%A Fu Ying, Wang Huaqing %T PI3K inhibitors in the treatment of lymphoma： present and challenges %0 Journal Article %D 2024 %J Journal of International Oncology %R 10.3760/cma.j.cn371439-20240407-00111 %P 660-666 %V 51 %N 10 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_11506.shtml} %8 2024-10-08 %X

Abnormal activation of phosphoinositide 3-kinase （PI3K） pathway is one of the pathogenesis of malignant lymphoma. PI3K inhibitors are new targets for lymphoma treatment in recent years. At present， a variety of different types of PI3K inhibitors have been developed， some of which have been approved for clinical use， and some are still in clinical trials. PI3K inhibitors have multiple side effects. Improving safety and efficacy is an important direction for the future development of PI3K inhibitors.